Post-market Clinical Follow-up (PMCF) Study of Safety and Performance of 502-01 AnGelHA 2
ConditionWrinkles
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGlyance
About this trial
Post-market clinical follow-up (PMCF) investigation to evaluate the performance and safety of AnGelHA 2 filler for the correction of moderate to severe wrinkles and folds and facial contour remodeling, in a routine clinical setting.
Eligibility criteria
Qualifiers
Men or women of any race, 18 years of age or older.
Able to read, understand and sign informed consent.
Disqualifiers
Pregnant or lactating women (contraindications as per IFU).
Having received prior dermal filler injections in the six months preceding the study.
Previously treated with semi-permanent or permanent filler in the intended injection area.
Presenting with a cutaneous disorder, inflammation or infection near to the treatment area.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
87 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov